[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[H.R. 8454 Enrolled Bill (ENR)]

        H.R.8454

                    One Hundred Seventeenth Congress

                                 of the

                        United States of America


                          AT THE SECOND SESSION

           Begun and held at the City of Washington on Monday,
          the third day of January, two thousand and twenty-two


                                 An Act


 
To expand research on cannabidiol and marijuana, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,
SECTION 1. SHORT TITLE; TABLE OF CONTENTS.
    (a) Short Title.--This Act may be cited as the ``Medical Marijuana 
and Cannabidiol Research Expansion Act''.
    (b) Table of Contents.--The table of contents for this Act is as 
follows:
Sec. 1. Short title; table of contents.
Sec. 2. Definitions.
Sec. 3. Determination of budgetary effects.

              TITLE I--REGISTRATIONS FOR MARIJUANA RESEARCH

Sec. 101. Marijuana research applications.
Sec. 102. Research protocols.
Sec. 103. Applications to manufacture marijuana for research.
Sec. 104. Adequate and uninterrupted supply.
Sec. 105. Security requirements.
Sec. 106. Prohibition against reinstating interdisciplinary review 
          process for non-NIH-funded researchers.

   TITLE II--DEVELOPMENT OF FDA-APPROVED DRUGS USING CANNABIDIOL AND 
                                MARIJUANA

Sec. 201. Medical research on cannabidiol.
Sec. 202. Registration for the commercial production and distribution of 
          Food and Drug Administration-approved drugs.

                 TITLE III--DOCTOR-PATIENT RELATIONSHIP

Sec. 301. Doctor-patient relationship.

                       TITLE IV--FEDERAL RESEARCH

Sec. 401. Federal research.
SEC. 2. DEFINITIONS.
    (a) In General.--In this Act--
        (1) the term ``appropriately registered'' means that an 
    individual or entity is registered under the Controlled Substances 
    Act (21 U.S.C. 801 et seq.) to engage in the type of activity that 
    is carried out by the individual or entity with respect to a 
    controlled substance on the schedule that is applicable to 
    cannabidiol or marijuana, as applicable;
        (2) the term ``cannabidiol'' means--
            (A) the substance, cannabidiol, as derived from marijuana 
        that has a delta-9-tetrahydrocannabinol level that is greater 
        than 0.3 percent; and
            (B) the synthetic equivalent of the substance described in 
        subparagraph (A);
        (3) the terms ``controlled substance'', ``dispense'', 
    ``distribute'', ``manufacture'', ``marijuana'', and 
    ``practitioner'' have the meanings given such terms in section 102 
    of the Controlled Substances Act (21 U.S.C. 802), as amended by 
    this Act;
        (4) the term ``covered institution of higher education'' means 
    an institution of higher education (as defined in section 101 of 
    the Higher Education Act of 1965 (20 U.S.C. 1001)) that--
            (A)(i) has highest or higher research activity, as defined 
        by the Carnegie Classification of Institutions of Higher 
        Education; or
            (ii) is an accredited medical school or an accredited 
        school of osteopathic medicine; and
            (B) is appropriately registered under the Controlled 
        Substances Act (21 U.S.C. 801 et seq.);
        (5) the term ``drug'' has the meaning given the term in section 
    201(g)(1) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
    321(g)(1));
        (6) the term ``medical research for drug development'' means 
    medical research that is--
            (A) a preclinical study or clinical investigation conducted 
        in accordance with section 505(i) of the Federal Food, Drug, 
        and Cosmetic Act (21 U.S.C. 355(i)) or otherwise permitted by 
        the Department of Health and Human Services to determine the 
        potential medical benefits of marijuana or cannabidiol as a 
        drug; and
            (B) conducted by a covered institution of higher education, 
        practitioner, or manufacturer that is appropriately registered 
        under the Controlled Substances Act (21 U.S.C. 801 et seq.); 
        and
        (7) the term ``State'' means any State of the United States, 
    the District of Columbia, and any territory of the United States.
    (b) Updating Term.--Section 102(16) of the Controlled Substances 
Act (21 U.S.C. 802(16)) is amended--
        (1) in subparagraph (A), by striking ``the term `marihuana' 
    means'' and inserting ``the terms `marihuana' and `marijuana' 
    mean''; and
        (2) in subparagraph (B), by striking ``The term `marihuana' 
    does not'' and inserting ``The terms `marihuana' and `marijuana' do 
    not''.
SEC. 3. DETERMINATION OF BUDGETARY EFFECTS.
    The budgetary effects of this Act, for the purpose of complying 
with the Statutory Pay-As-You-Go Act of 2010, shall be determined by 
reference to the latest statement titled ``Budgetary Effects of PAYGO 
Legislation'' for this Act, submitted for printing in the Congressional 
Record by the Chairman of the House Budget Committee, provided that 
such statement has been submitted prior to the vote on passage.

             TITLE I--REGISTRATIONS FOR MARIJUANA RESEARCH

    SEC. 101. MARIJUANA RESEARCH APPLICATIONS.
    Section 303(f) of the Controlled Substances Act (21 U.S.C. 823(f)) 
is amended--
        (1) by redesignating paragraphs (1) through (5) as 
    subparagraphs (A) through (E), respectively;
        (2) by striking ``(f) The Attorney General'' and inserting 
    ``(f)(1) The Attorney General'';
        (3) by striking ``Registration applications'' and inserting the 
    following:
    ``(2)(A) Registration applications'';
        (4) by striking ``Article 7'' and inserting the following:
    ``(3) Article 7''; and
        (5) by inserting after paragraph (2)(A), as so designated, the 
    following:
    ``(B)(i) The Attorney General shall register a practitioner to 
conduct research with marijuana (including any derivative, extract, 
preparation, and compound thereof) if--
        ``(I) the applicant's research protocol has been reviewed and 
    allowed--
            ``(aa) by the Secretary of Health and Human Services under 
        section 505(i) of the Federal Food, Drug, and Cosmetic Act (21 
        U.S.C. 355(i));
            ``(bb) by the National Institutes of Health or another 
        Federal agency that funds scientific research; or
            ``(cc) pursuant to sections 1301.18 and 1301.32 of title 
        21, Code of Federal Regulations, or any successors thereto; and
        ``(II) the applicant has demonstrated to the Attorney General 
    that there are effective procedures in place to adequately 
    safeguard against diversion of the controlled substance for 
    legitimate medical or scientific use pursuant to section 105 of the 
    Medical Marijuana and Cannabidiol Research Expansion Act, including 
    demonstrating that the security measures are adequate for storing 
    the quantity of marijuana the applicant would be authorized to 
    possess.
    ``(ii) The Attorney General may deny an application for 
registration under this subparagraph only if the Attorney General 
determines that the issuance of the registration would be inconsistent 
with the public interest. In determining the public interest, the 
Attorney General shall consider the factors listed in--
        ``(I) subparagraphs (B) through (E) of paragraph (1); and
        ``(II) subparagraph (A) of paragraph (1), if the applicable 
    State requires practitioners conducting research to register with a 
    board or authority described in such subparagraph (A).
    ``(iii)(I) Not later than 60 days after the date on which the 
Attorney General receives a complete application for registration under 
this subparagraph, the Attorney General shall--
        ``(aa) approve the application; or
        ``(bb) request supplemental information.
    ``(II) For purposes of subclause (I), an application shall be 
deemed complete when the applicant has submitted documentation showing 
that the requirements under clause (i) are satisfied.
    ``(iv) Not later than 30 days after the date on which the Attorney 
General receives supplemental information as described in clause 
(iii)(I)(bb) in connection with an application described in this 
subparagraph, the Attorney General shall approve or deny the 
application.
    ``(v) If an application described in this subparagraph is denied, 
the Attorney General shall provide a written explanation of the basis 
of denial to the applicant.''.
    SEC. 102. RESEARCH PROTOCOLS.
    (a) In General.--Paragraph (2)(B) of section 303(f) of the 
Controlled Substances Act (21 U.S.C. 823(f)), as added by section 101 
of this Act, is further amended by adding at the end the following:
    ``(vi)(I) If the Attorney General grants an application for 
registration under clause (i), the registrant may amend or supplement 
the research protocol without notification to, or review by, the Drug 
Enforcement Administration if the registrant does not change--
        ``(aa) the quantity or type of marijuana or cannabidiol 
    (including any derivative, extract, preparation, and compound 
    thereof);
        ``(bb) the source of such marijuana or cannabidiol; or
        ``(cc) the conditions under which such marijuana or cannabidiol 
    is stored, tracked, or administered.
    ``(II)(aa) If a registrant under clause (i) seeks to change the 
type of marijuana or cannabidiol (including any derivative, extract, 
preparation, and compound thereof), the source of such marijuana or 
cannabidiol, or the conditions under which such marijuana or 
cannabidiol is stored, tracked, or administered, the registrant shall 
notify the Attorney General via registered mail, or an electronic means 
permitted by the Attorney General, not later than 30 days before 
implementing an amended or supplemental research protocol.
    ``(bb) A registrant may proceed with an amended or supplemental 
research protocol described in item (aa) if the Attorney General does 
not explicitly object during the 30-day period beginning on the date on 
which the Attorney General receives the notice under item (aa).
    ``(cc) The Attorney General may only object to an amended or 
supplemental research protocol under this subclause if additional 
security measures are needed to safeguard against diversion or abuse.
    ``(dd) If a registrant under clause (i) seeks to address additional 
security measures identified by the Attorney General under item (cc), 
the registrant shall notify the Attorney General via registered mail, 
or an electronic means permitted by the Attorney General, not later 
than 30 days before implementing an amended or supplemental research 
protocol.
    ``(ee) A registrant may proceed with an amended or supplemental 
research protocol described in item (dd) if the Attorney General does 
not explicitly object during the 30-day period beginning on the date on 
which the Attorney General receives the notice under item (dd).
    ``(III)(aa) If a registrant under clause (i) seeks to change the 
quantity of marijuana needed for research and the change in quantity 
does not impact the factors described in item (bb) or (cc) of subclause 
(I) of this clause, the registrant shall notify the Attorney General 
via registered mail or using an electronic means permitted by the 
Attorney General.
    ``(bb) A notification under item (aa) shall include--
        ``(AA) the Drug Enforcement Administration registration number 
    of the registrant;
        ``(BB) the quantity of marijuana or cannabidiol already 
    obtained;
        ``(CC) the quantity of additional marijuana or cannabidiol 
    needed to complete the research; and
        ``(DD) an attestation that the change in quantity does not 
    impact the source of the marijuana or cannabidiol or the conditions 
    under which the marijuana or cannabidiol is stored, tracked, or 
    administered.
    ``(cc) The Attorney General shall ensure that--
        ``(AA) any registered mail return receipt with respect to a 
    notification under item (aa) is submitted for delivery to the 
    registrant providing the notification not later than 3 days after 
    receipt of the notification by the Attorney General; and
        ``(BB) notice of receipt of a notification using an electronic 
    means permitted under item (aa) is provided to the registrant 
    providing the notification not later than 3 days after receipt of 
    the notification by the Attorney General.
    ``(dd)(AA) On and after the date described in subitem (BB), a 
registrant that submits a notification in accordance with item (aa) may 
proceed with the research as if the change in quantity has been 
approved on such date, unless the Attorney General notifies the 
registrant of an objection described in item (ee).
    ``(BB) The date described in this subitem is the date on which a 
registrant submitting a notification under item (aa) receives the 
registered mail return receipt with respect to the notification or the 
date on which the registrant receives notice that the notification 
using an electronic means permitted under item (aa) was received by the 
Attorney General, as the case may be.
    ``(ee) A notification submitted under item (aa) shall be deemed to 
be approved unless the Attorney General, not later than 10 days after 
receiving the notification, explicitly objects based on a finding that 
the change in quantity--
        ``(AA) does impact the source of the marijuana or cannabidiol 
    or the conditions under which the marijuana or cannabidiol is 
    stored, tracked, or administered; or
        ``(BB) necessitates that the registrant implement additional 
    security measures to safeguard against diversion or abuse.
    ``(IV) Nothing in this clause shall limit the authority of the 
Secretary of Health and Human Services over requirements related to 
research protocols, including changes in--
        ``(aa) the method of administration of marijuana or 
    cannabidiol;
        ``(bb) the dosing of marijuana or cannabidiol; and
        ``(cc) the number of individuals or patients involved in 
    research.''.
    (b) Regulations.--Not later than 1 year after the date of enactment 
of this Act, the Attorney General shall promulgate regulations to carry 
out the amendment made by this section.
    SEC. 103. APPLICATIONS TO MANUFACTURE MARIJUANA FOR RESEARCH.
    (a) In General.--Section 303 of the Controlled Substances Act (21 
U.S.C. 823), as amended by sections 101 and 102 of this Act, is further 
amended--
        (1) by redesignating subsections (c) through (k) as subsections 
    (d) through (l), respectively;
        (2) by inserting after subsection (b) the following:
    ``(c)(1)(A) As it relates to applications to manufacture marijuana 
for research purposes, when the Attorney General places a notice in the 
Federal Register to increase the number of entities registered under 
this Act to manufacture marijuana to supply appropriately registered 
researchers in the United States, the Attorney General shall, not later 
than 60 days after the date on which the Attorney General receives a 
completed application--
        ``(i) approve the application; or
        ``(ii) request supplemental information.
    ``(B) For purposes of subparagraph (A), an application shall be 
deemed complete when the applicant has submitted documentation showing 
each of the following:
        ``(i) The requirements designated in the notice in the Federal 
    Register are satisfied.
        ``(ii) The requirements under this Act are satisfied.
        ``(iii) The applicant will limit the transfer and sale of any 
    marijuana manufactured under this subsection--
            ``(I) to researchers who are registered under this Act to 
        conduct research with controlled substances in schedule I; and
            ``(II) for purposes of use in preclinical research or in a 
        clinical investigation pursuant to an investigational new drug 
        exemption under 505(i) of the Federal Food, Drug, and Cosmetic 
        Act (21 U.S.C. 355(i)).
        ``(iv) The applicant will transfer or sell any marijuana 
    manufactured under this subsection only with prior, written consent 
    for the transfer or sale by the Attorney General.
        ``(v) The applicant has completed the application and review 
    process under subsection (a) for the bulk manufacture of controlled 
    substances in schedule I.
        ``(vi) The applicant has established and begun operation of a 
    process for storage and handling of controlled substances in 
    schedule I, including for inventory control and monitoring security 
    in accordance with section 105 of the Medical Marijuana and 
    Cannabidiol Research Expansion Act.
        ``(vii) The applicant is licensed by each State in which the 
    applicant will conduct operations under this subsection, to 
    manufacture marijuana, if that State requires such a license.
    ``(C) Not later than 30 days after the date on which the Attorney 
General receives supplemental information requested under subparagraph 
(A)(ii) with respect to an application, the Attorney General shall 
approve or deny the application.
    ``(2) If an application described in this subsection is denied, the 
Attorney General shall provide a written explanation of the basis of 
denial to the applicant.'';
        (3) in subsection (h)(2), as so redesignated, by striking 
    ``subsection (f)'' each place it appears and inserting ``subsection 
    (g)'';
        (4) in subsection (j)(1), as so redesignated, by striking 
    ``subsection (d)'' and inserting ``subsection (e)''; and
        (5) in subsection (k), as so redesignated, by striking 
    ``subsection (f)'' each place it appears and inserting ``subsection 
    (g)''.
    (b) Technical and Conforming Amendments.--
        (1) The Controlled Substances Act (21 U.S.C. 801 et seq.) is 
    amended--
            (A) in section 102 (21 U.S.C. 802)--
                (i) in paragraph (52)(B)--

                    (I) by striking ``303(f)'' each place it appears 
                and inserting ``303(g)''; and
                    (II) in clause (i), by striking ``(d), or (e)'' and 
                inserting ``(e), or (f)''; and

                (ii) in paragraph (54), by striking ``303(f)'' each 
            place it appears and inserting ``303(g)'';
            (B) in section 302(g)(5)(A)(iii)(I)(bb) (21 U.S.C. 
        822(g)(5)(A)(iii)(I)(bb)), by striking ``303(f)'' and inserting 
        ``303(g)'';
            (C) in section 304 (21 U.S.C. 824), by striking 
        ``303(g)(1)'' each place it appears and inserting 
        ``303(h)(1)'';
            (D) in section 307(d)(2) (21 U.S.C. 827(d)(2)), by striking 
        ``303(f)'' and inserting ``303(g)'';
            (E) in section 309A(a)(2) (21 U.S.C. 829a(a)(2)), in the 
        matter preceding subparagraph (A), by striking ``303(g)(2)'' 
        and inserting ``303(h)(2)'';
            (F) in section 311(h) (21 U.S.C. 831(h)), by striking 
        ``303(f)'' each place it appears and inserting ``303(g)'';
            (G) in section 401(h)(2) (21 U.S.C. 841(h)(2)), by striking 
        ``303(f)'' each place it appears and inserting ``303(g)'';
            (H) in section 403(c)(2)(B) (21 U.S.C. 843(c)(2)(B)), by 
        striking ``303(f)'' and inserting ``303(g)''; and
            (I) in section 512(c)(1) (21 U.S.C. 882(c)(1)) by striking 
        ``303(f)'' and inserting ``303(g)''.
        (2) Section 1008(c) of the Controlled Substances Import and 
    Export Act (21 U.S.C. 958(c)) is amended--
            (A) in paragraph (1), by striking ``303(d)'' and inserting 
        ``303(e)''; and
            (B) in paragraph (2)(B), by striking ``303(h)'' and 
        inserting ``303(i)''.
        (3) Title V of the Public Health Service Act (42 U.S.C. 290aa 
    et seq.) is amended--
            (A) in section 520E-4(c) (42 U.S.C. 290bb-36d(c)), by 
        striking ``303(g)(2)(B)'' and inserting ``303(h)(2)(B)''; and
            (B) in section 544(a)(3) (42 U.S.C. 290dd-3(a)(3)), by 
        striking ``303(g)'' and inserting ``303(h)''.
        (4) Title XVIII of the Social Security Act (42 U.S.C. 1395 et 
    seq.) is amended--
            (A) in section 1833(bb)(3)(B) (42 U.S.C. 1395l(bb)(3)(B)), 
        by striking ``303(g)'' and inserting ``303(h)'';
            (B) in section 1834(o)(3)(C)(ii) (42 U.S.C. 
        1395m(o)(3)(C)(ii)), by striking ``303(g)'' and inserting 
        ``303(h)''; and
            (C) in section 1866F(c)(3)(C) (42 U.S.C. 1395cc-
        6(c)(3)(C)), by striking ``303(g)'' and inserting ``303(h)''.
        (5) Section 1903(aa)(2)(C)(ii) of the Social Security Act (42 
    U.S.C. 1396b(aa)(2)(C)(ii)) is amended by striking ``303(g)'' each 
    place it appears and inserting ``303(h)''.
    SEC. 104. ADEQUATE AND UNINTERRUPTED SUPPLY.
    (a) In General.--On an annual basis, the Attorney General, in 
consultation with the Secretary of Health and Human Services, shall 
assess whether there is an adequate and uninterrupted supply of 
marijuana, including of specific strains, for research purposes.
    (b) Report to Congress.--If the Attorney General, in consultation 
with the Secretary of Health and Human Services, determines there is an 
inadequate or interrupted supply of marijuana, including of specific 
strains for research purposes, the Attorney General shall report to 
Congress within 60 days of the determination on at least--
        (1) the factors contributing to the inadequate or interrupted 
    supply of marijuana;
        (2) expected impacts of the inadequate or interrupted supply on 
    ongoing research protocols; and
        (3) specific steps the Attorney General will take to restore an 
    adequate and uninterrupted supply of marijuana, including of 
    specific strains, for research purposes.
    SEC. 105. SECURITY REQUIREMENTS.
    (a) In General.--An individual or entity engaged in researching 
marijuana or its components shall store it in a securely locked, 
substantially constructed cabinet.
    (b) Requirements for Other Measures.--Any other security measures 
required by the Attorney General to safeguard against diversion shall 
be consistent with those required for practitioners conducting research 
on other controlled substances in schedules I and II in section 202(c) 
of the Controlled Substances Act (21 U.S.C. 812(c)) that have a similar 
risk of diversion and abuse.
    SEC. 106. PROHIBITION AGAINST REINSTATING INTERDISCIPLINARY REVIEW 
      PROCESS FOR NON-NIH-FUNDED RESEARCHERS.
    The Secretary of Health and Human Services may not--
        (1) reinstate the Public Health Service interdisciplinary 
    review process described in the guidance entitled ``Guidance on 
    Procedures for the Provision of Marijuana for Medical Research'' 
    (issued on May 21, 1999); or
        (2) require another review of scientific protocols that is 
    applicable only to research on marijuana or its components.

   TITLE II--DEVELOPMENT OF FDA-APPROVED DRUGS USING CANNABIDIOL AND 
                               MARIJUANA

    SEC. 201. MEDICAL RESEARCH ON CANNABIDIOL.
    Notwithstanding any provision of the Controlled Substances Act (21 
U.S.C. 801 et seq.), the Safe and Drug-Free Schools and Communities Act 
(20 U.S.C. 7101 et seq.), chapter 81 of title 41, United States Code, 
or any other Federal law, an appropriately registered covered 
institution of higher education, practitioner, or manufacturer may 
manufacture, distribute, dispense, or possess marijuana or cannabidiol 
if the marijuana or cannabidiol is manufactured, distributed, 
dispensed, or possessed, respectively, for purposes of medical research 
for drug development or subsequent commercial production in accordance 
with section 202.
    SEC. 202. REGISTRATION FOR THE COMMERCIAL PRODUCTION AND 
      DISTRIBUTION OF FOOD AND DRUG ADMINISTRATION-APPROVED DRUGS.
    The Attorney General shall register an applicant to manufacture or 
distribute cannabidiol or marijuana for the purpose of commercial 
production of a drug containing or derived from marijuana that is 
approved by the Secretary of Health and Human Services under section 
505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355), in 
accordance with the applicable requirements under subsection (a) or (b) 
of section 303 of the Controlled Substances Act (21 U.S.C. 823).

                 TITLE III--DOCTOR-PATIENT RELATIONSHIP

    SEC. 301. DOCTOR-PATIENT RELATIONSHIP.
    It shall not be a violation of the Controlled Substances Act (21 
U.S.C. 801 et seq.) for a State-licensed physician to discuss--
        (1) the currently known potential harms and benefits of 
    marijuana derivatives, including cannabidiol, as a treatment with 
    the legal guardian of the patient of the physician if the patient 
    is a child; or
        (2) the currently known potential harms and benefits of 
    marijuana and marijuana derivatives, including cannabidiol, as a 
    treatment with the patient or the legal guardian of the patient of 
    the physician if the patient is a legal adult.

                       TITLE IV--FEDERAL RESEARCH

    SEC. 401. FEDERAL RESEARCH.
    (a) In General.--Not later than 1 year after the date of enactment 
of this Act, the Secretary of Health and Human Services, in 
coordination with the Director of the National Institutes of Health and 
the heads of other relevant Federal agencies, shall submit to the 
Caucus on International Narcotics Control, the Committee on the 
Judiciary, and the Committee on Health, Education, Labor, and Pensions 
of the Senate and the Committee on Energy and Commerce and the 
Committee on the Judiciary of the House of Representatives a report 
on--
        (1) the potential therapeutic effects of cannabidiol or 
    marijuana on serious medical conditions, including intractable 
    epilepsy;
        (2) the potential effects of marijuana, including--
            (A) the effect of increasing delta-9-tetrahydrocannabinol 
        levels on the human body and developing adolescent brains; and
            (B) the effect of various delta-9-tetrahydrocannabinol 
        levels on cognitive abilities, such as those that are required 
        to operate motor vehicles or other heavy equipment; and
        (3) the barriers associated with researching marijuana or 
    cannabidiol in States that have legalized the use of such 
    substances, which shall include--
            (A) recommendations as to how such barriers might be 
        overcome, including whether public-private partnerships or 
        Federal-State research partnerships may or should be 
        implemented to provide researchers with access to additional 
        strains of marijuana and cannabidiol; and
            (B) recommendations as to what safeguards must be in place 
        to verify--
                (i) the levels of tetrahydrocannabinol, cannabidiol, or 
            other cannabinoids contained in products obtained from such 
            States is accurate; and
                (ii) that such products do not contain harmful or toxic 
            components.
    (b) Activities.--To the extent practicable, the Secretary of Health 
and Human Services, either directly or through awarding grants, 
contacts, or cooperative agreements, shall expand and coordinate the 
activities of the National Institutes of Health and other relevant 
Federal agencies to better determine the effects of cannabidiol and 
marijuana, as outlined in the report submitted under paragraphs (1) and 
(2) of subsection (a).

                               Speaker of the House of Representatives.

                            Vice President of the United States and    
                                               President of the Senate.